Zhang Mei, Zhao Yun-feng, Luo Yi-min, Wang Xi-hua, Yang Yuan, Lin Yong
Respiratory Department, Zhongda Hospital, Southeast University, Nanjing 210009, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2013 Apr;36(4):269-73.
To investigate the value of coexisting pneumonia and British Thoracic Society CURB-65 score in predicting early mortality in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).
In this prospective study, 483 consecutive in-patients with AECOPD were recruited between January 2010 and September 2012, including 295 males and 188 females. The patients were aged 45 to 92 years. They were divided into 2 groups: non-pneumonia (npAECOPD) and with pneumonia (pAECOPD). The start point of this study was the date when the patients were admitted into the respiratory ward, and the endpoint was the 30 day mortality. Clinical and demographic data were collected for all the patients, and the value of coexisting pneumonia and CURB-65 in predicting in-hospital mortality and 30 day mortality were assessed and compared.
According to the inclusion/exclusion criteria, eventually 457 patients were included in this research, with 278 males and 179 females, and an average age of (75 ± 9) years. Of the 457 patients, 120 (26.3%) patients were in the pAECOPD group and 337 (73.7%) patients in the npAECOPD group. The in-hospital mortality, the 30 day mortality and the assisted ventilation rate were significantly higher in the pAECOPD group as compared to the npAECOPD group 18.3% (22/120) vs 4.7% (16/337), 21.7% (26/120) vs 7.4% (25/337); 49.2% (59/120) vs 27.0% (91/337), χ(2) = 18.1 - 21.4, all P < 0.05, respectively. Furthermore, the in-hospital mortality of the pAECOPD patients with CURB-65 score < 2, = 2 and > 2 was 4.4% (2/45), 15.2% (7/46) and 44.8% (13/29), respectively, while that of the npAECOPD patients was 0.9% (1/113), 3.4% (4/119) and 10.5% (11/105), respectively. The 30 day mortality of the pAECOPD patients with CURB-65 score < 2, = 2 and > 2 was 4.4% (2/45), 19.6% (9/46) and 51.7% (15/29), respectively, while that of the npAECOPD patients was 0.9% (1/113), 5.0% (6/119) and 17.1% (18/105), respectively. Stratified by CURB-65 Score, the in-hospital and 30 day mortality were both significantly higher in the pAECOPD group than in the npAECOPD group when CURB-65 was ≥ 2 (χ(2) = 5.8 - 10.1, P < 0.05 and P < 0.01, respectively). The AUROC analysis of CURB-65 as a predictor for early mortality resulted in an area under curve of 0.744.
In patients with AECOPD, coexisting pneumonia is not only a risk factor for in-hospital mortality, but also a predictor for the treatment of assisted ventilation. CURB-65 score may be a good predictor for early mortality in patients with AECOPD.
探讨合并肺炎及英国胸科学会CURB - 65评分对慢性阻塞性肺疾病急性加重期(AECOPD)患者早期死亡率的预测价值。
在这项前瞻性研究中,于2010年1月至2012年9月连续纳入483例AECOPD住院患者,其中男性295例,女性188例。患者年龄在45至92岁之间。他们被分为两组:无肺炎组(npAECOPD)和合并肺炎组(pAECOPD)。本研究的起始点为患者入住呼吸病房的日期,终点为30天死亡率。收集所有患者的临床和人口统计学数据,并评估和比较合并肺炎及CURB - 65评分对住院死亡率和30天死亡率的预测价值。
根据纳入/排除标准,最终457例患者纳入本研究,其中男性278例,女性179例,平均年龄(75±9)岁。在457例患者中,pAECOPD组120例(26.3%),npAECOPD组337例(73.7%)。与npAECOPD组相比,pAECOPD组的住院死亡率、30天死亡率及辅助通气率显著更高,分别为18.3%(22/120)对4.7%(16/337),21.7%(26/120)对7.4%(25/337);49.2%(59/120)对27.0%(91/337),χ(2)=18.1 - 21.4,均P<0.05。此外,CURB - 65评分<2、=2及>2的pAECOPD患者的住院死亡率分别为4.4%(2/45)、15.2%(7/46)和44.8%(13/29),而npAECOPD患者分别为0.9%(1/113)、3.4%(4/119)和10.5%(11/105)。CURB - 65评分<2、=2及>2的pAECOPD患者的30天死亡率分别为4.4%(2/45)、19.6%(9/46)和51.7%(15/29),而npAECOPD患者分别为0.9%(1/113)、5.0%(6/119)和17.1%(18/105)。按CURB - 65评分分层,当CURB - 65≥2时,pAECOPD组的住院死亡率和30天死亡率均显著高于npAECOPD组(χ(2)=5.8 - 10.1,P<0.05和P<0.01)。CURB - 65作为早期死亡率预测指标的受试者工作特征曲线下面积(AUROC)分析结果为0.744。
在AECOPD患者中,合并肺炎不仅是住院死亡率的危险因素,也是辅助通气治疗的预测指标。CURB - 65评分可能是AECOPD患者早期死亡率的良好预测指标。